Malaysia
· Delayed Price · Currency is MYR Pharmaniaga Berhad Statistics
Total Valuation
Pharmaniaga Berhad has a market cap or net worth of MYR 547.67 million. The enterprise value is 1.72 billion.
| Market Cap | 547.67M |
| Enterprise Value | 1.72B |
Important Dates
The next estimated earnings date is Friday, November 22, 2024.
| Earnings Date | Nov 22, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharmaniaga Berhad has 1.44 billion shares outstanding. The number of shares has increased by 9.39% in one year.
| Shares Outstanding | 1.44B |
| Shares Change (YoY) | +9.39% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 4.19% |
| Owned by Institutions (%) | 10.74% |
| Float | 463.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 10.86 |
| PS Ratio | 0.16 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 34.89, with an EV/FCF ratio of -15.48.
| EV / Earnings | -30.45 |
| EV / Sales | 0.49 |
| EV / EBITDA | 34.89 |
| EV / EBIT | 146.95 |
| EV / FCF | -15.48 |
Financial Position
The company has a current ratio of 0.59
| Current Ratio | 0.59 |
| Quick Ratio | 0.31 |
| Debt / Equity | n/a |
| Debt / EBITDA | 24.59 |
| Debt / FCF | -10.91 |
| Interest Coverage | 0.17 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 0.35% |
| Return on Capital (ROIC) | 0.73% |
| Revenue Per Employee | 1.00M |
| Profits Per Employee | -16,204 |
| Employee Count | 3,476 |
| Asset Turnover | 1.68 |
| Inventory Turnover | 4.97 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -9.30% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -9.30% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 0.38 |
| Relative Strength Index (RSI) | 44.67 |
| Average Volume (20 Days) | 1,036,890 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmaniaga Berhad had revenue of MYR 3.48 billion and -56.33 million in losses. Loss per share was -0.04.
| Revenue | 3.48B |
| Gross Profit | 323.56M |
| Operating Income | 11.67M |
| Pretax Income | -51.32M |
| Net Income | -56.33M |
| EBITDA | 38.19M |
| EBIT | 11.67M |
| Loss Per Share | -0.04 |
Balance Sheet
The company has 66.77 million in cash and 1.21 billion in debt, giving a net cash position of -1.14 billion or -0.79 per share.
| Cash & Cash Equivalents | 66.77M |
| Total Debt | 1.21B |
| Net Cash | -1.14B |
| Net Cash Per Share | -0.79 |
| Equity (Book Value) | -247.39M |
| Book Value Per Share | -0.19 |
| Working Capital | -882.01M |
Cash Flow
In the last 12 months, operating cash flow was -59.91 million and capital expenditures -50.90 million, giving a free cash flow of -110.81 million.
| Operating Cash Flow | -59.91M |
| Capital Expenditures | -50.90M |
| Free Cash Flow | -110.81M |
| FCF Per Share | -0.08 |
Margins
Gross margin is 9.30%, with operating and profit margins of 0.34% and -1.62%.
| Gross Margin | 9.30% |
| Operating Margin | 0.34% |
| Pretax Margin | -1.48% |
| Profit Margin | -1.62% |
| EBITDA Margin | 1.10% |
| EBIT Margin | 0.34% |
| FCF Margin | -3.19% |
Dividends & Yields
Pharmaniaga Berhad does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.39% |
| Shareholder Yield | -9.39% |
| Earnings Yield | -10.34% |
| FCF Yield | -20.23% |
Stock Splits
The last stock split was on July 5, 2021. It was a forward split with a ratio of 5.
| Last Split Date | Jul 5, 2021 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Pharmaniaga Berhad has an Altman Z-Score of 0.94. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.94 |
| Piotroski F-Score | n/a |